Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1991 Jun;31(6):665–670. doi: 10.1111/j.1365-2125.1991.tb05590.x

Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin.

H Y Pan 1, J Triscari 1, A R DeVault 1, S A Smith 1, D Wang-Iverson 1, B N Swanson 1, D A Willard 1
PMCID: PMC1368577  PMID: 1907839

Abstract

1. Single oral 20 mg doses of the HMG-CoA reductase inhibitors pravastatin and lovastatin, with and without concomitant propranolol (40 mg twice daily), were administered to 16 healthy male subjects participating in a randomized, four-way crossover study. 2. Serum concentrations of total and active inhibitors were measured by bioassay and concentrations of pravastatin, two pravastatin metabolites and lovastatin acid were measured by gas chromatography/mass spectrometry. 3. Coadministration of propranolol with pravastatin reduced the mean area under the serum concentration-time curve (AUC) of total inhibitors by 23%, of active inhibitors by 20% and of pravastatin by 16%. 4. Coadministration of propranolol with lovastatin also resulted in decreases in the mean serum AUC of total inhibitors by 18%, of active inhibitors by 12% and of lovastatin acid by 13%. 5. These decreases in systemic drug concentrations may reflect enhanced drug first-pass hepatic clearance in the presence of propranolol. 6. The clinical significance of these changes is likely to be small.

Full text

PDF
667

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberts A. W., Chen J., Kuron G., Hunt V., Huff J., Hoffman C., Rothrock J., Lopez M., Joshua H., Harris E. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A. 1980 Jul;77(7):3957–3961. doi: 10.1073/pnas.77.7.3957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bax N. D., Lennard M. S., Tucker G. T. Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists. Br J Clin Pharmacol. 1981 Dec;12(6):779–784. doi: 10.1111/j.1365-2125.1981.tb01306.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Conrad K. A., Byers J. M., 3rd, Finley P. R., Burnham L. Lidocaine elimination: effects of metoprolol and of propranolol. Clin Pharmacol Ther. 1983 Feb;33(2):133–138. doi: 10.1038/clpt.1983.20. [DOI] [PubMed] [Google Scholar]
  4. Conrad K. A., Nyman D. W. Effects of metoprolol and propranolol on theophylline elimination. Clin Pharmacol Ther. 1980 Oct;28(4):463–467. doi: 10.1038/clpt.1980.189. [DOI] [PubMed] [Google Scholar]
  5. Duggan D. E., Chen I. W., Bayne W. F., Halpin R. A., Duncan C. A., Schwartz M. S., Stubbs R. J., Vickers S. The physiological disposition of lovastatin. Drug Metab Dispos. 1989 Mar-Apr;17(2):166–173. [PubMed] [Google Scholar]
  6. Frishman W. H., Rapier R. C. Lovastatin: an HMG-CoA reductase inhibitor for lowering cholesterol. Med Clin North Am. 1989 Mar;73(2):437–448. doi: 10.1016/s0025-7125(16)30681-2. [DOI] [PubMed] [Google Scholar]
  7. Frishman W. H., Zimetbaum P., Nadelmann J. Lovastatin and other HMG-CoA reductase inhibitors. J Clin Pharmacol. 1989 Nov;29(11):975–982. doi: 10.1002/j.1552-4604.1989.tb03264.x. [DOI] [PubMed] [Google Scholar]
  8. Funke P. T., Ivashkiv E., Arnold M. E., Cohen A. I. Determination of pravastatin sodium and its major metabolites in human serum/plasma by capillary gas chromatography/negative ion chemical ionization mass spectrometry. Biomed Environ Mass Spectrom. 1989 Oct;18(10):904–909. doi: 10.1002/bms.1200181010. [DOI] [PubMed] [Google Scholar]
  9. Grundy S. M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988 Jul 7;319(1):24–33. doi: 10.1056/NEJM198807073190105. [DOI] [PubMed] [Google Scholar]
  10. Henwood J. M., Heel R. C. Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs. 1988 Oct;36(4):429–454. doi: 10.2165/00003495-198836040-00003. [DOI] [PubMed] [Google Scholar]
  11. Illingworth D. R., Bacon S. Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia. Am J Cardiol. 1987 Oct 30;60(12):33G–42G. doi: 10.1016/0002-9149(87)90589-3. [DOI] [PubMed] [Google Scholar]
  12. Krukemyer J. J., Talbert R. L. Lovastatin: a new cholesterol-lowering agent. Pharmacotherapy. 1987;7(6):198–210. doi: 10.1002/j.1875-9114.1987.tb03524.x. [DOI] [PubMed] [Google Scholar]
  13. Lewis R. V., McDevitt D. G. Adverse reactions and interactions with beta-adrenoceptor blocking drugs. Med Toxicol. 1986 Sep-Oct;1(5):343–361. doi: 10.1007/BF03259848. [DOI] [PubMed] [Google Scholar]
  14. McLean A. J., McNamara P. J., duSouich P., Gibaldi M., Lalka D. Food, splanchnic blood flow, and bioavailability of drugs subject to first-pass metabolism. Clin Pharmacol Ther. 1978 Jul;24(1):5–10. doi: 10.1002/cpt19782415. [DOI] [PubMed] [Google Scholar]
  15. Nakaya N., Homma Y., Tamachi H., Shigematsu H., Hata Y., Goto Y. The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects. JAMA. 1987 Jun 12;257(22):3088–3093. [PubMed] [Google Scholar]
  16. Ochs H. R., Carstens G., Greenblatt D. J. Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol. N Engl J Med. 1980 Aug 14;303(7):373–377. doi: 10.1056/NEJM198008143030705. [DOI] [PubMed] [Google Scholar]
  17. Ochs H. R., Greenblatt D. J., Verburg-Ochs B. Propranolol interactions with diazepam, lorazepam, and alprazolam. Clin Pharmacol Ther. 1984 Oct;36(4):451–455. doi: 10.1038/clpt.1984.203. [DOI] [PubMed] [Google Scholar]
  18. Shepherd A. N., Hayes P. C., Jacyna M., Morrison L., Bouchier I. A. The influence of captopril, the nitrates and propranolol on apparent liver blood flow. Br J Clin Pharmacol. 1985 Mar;19(3):393–397. doi: 10.1111/j.1365-2125.1985.tb02659.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Singhvi S. M., Pan H. Y., Morrison R. A., Willard D. A. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol. 1990 Feb;29(2):239–243. doi: 10.1111/j.1365-2125.1990.tb03626.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Tsujita Y., Kuroda M., Shimada Y., Tanzawa K., Arai M., Kaneko I., Tanaka M., Masuda H., Tarumi C., Watanabe Y. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta. 1986 Jun 11;877(1):50–60. doi: 10.1016/0005-2760(86)90117-7. [DOI] [PubMed] [Google Scholar]
  21. Tucker G. T., Bax N. D., Lennard M. S., Al-Asady S., Bharaj H. S., Woods H. F. Effects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine. Br J Clin Pharmacol. 1984;17 (Suppl 1):21S–28S. doi: 10.1111/j.1365-2125.1984.tb02424.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wang-Iverson D., Ivashkiv E., Jemal M., Cohen A. I. Determination of lovastatin acid in serum by gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom. 1989 May;3(5):132–134. doi: 10.1002/rcm.1290030504. [DOI] [PubMed] [Google Scholar]
  23. Wood A. J., Feely J. Pharmacokinetic drug interactions with propranolol. Clin Pharmacokinet. 1983 May-Jun;8(3):253–262. doi: 10.2165/00003088-198308030-00004. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES